OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary ...

Detailed price information for Os Therapies Incorporated (OSTX-A) from The Globe and Mail including charting and trades.

OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting

Detailed price information for Os Therapies Incorporated (OSTX-A) from The Globe and Mail including charting and trades.

What No One Tells You About Typhoid Recovery: Survivor Explains Fatigue, Taste Changes And More

The bacterial infection typhoid fever may clear, but its impact often doesn't. From gut-damage and liver stress to persistent ...

Pneumococcal Vaccine Research Report 2025: A $14.9 Billion Market by 2033, Driven by Rising Sepsis and Pneumonia Cases, Aging Populations, Healthcare Funding, and Advances in ...

Key market opportunities in the pneumococcal vaccine sector include rising demand due to an aging population and increasing healthcare spend, advanced vaccine technology, and global health initiatives ...
Le Lézard

Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025

Gilead Sciences, Inc. and Kite, a Gilead Company, will present 21 abstracts, including 5 oral presentations, during the 67th American Society of Hematology (ASH) Annual Meeting and Exposition ...